A non-DRE, voided urine, genomic assay to diagnose prostate cancer and to assess its aggressiveness.
Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
Survival benefit of maintenance therapy in AML patients after complete remission in northeast Iran oncology centers with limited access to oral azacitidine. VPAC/MDx sensitivity and specificity in PEP ...
Introduction Self-sampling for cervical cancer screening is a promising strategy to improve coverage and reduce strain on ...
Aranan Tarih Aralığı: 2026-1-3 / 2026-01-04 Aranan Kelime: a federally funded research study involving children 8 to 12 years old involves collecting a single voided urine sample to assess the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results